Lowering your risk of metabolic syndrome involves a multi-faceted approach, focusing on diet, exercise, and careful monitoring of key metabolic markers.
Our read is that metabolic syndrome, a constellation of five conditions including increased blood glucose and abdominal obesity, is well-supported to be lowered through various metabolic approaches.
Experts suggest that dietary choices, exercise, and understanding individual metabolic markers are crucial for prevention and management.
While some dietary components are highlighted as detrimental, others are noted for their potential benefits in improving metabolic health.
Physicians can use body fat percentage, visceral fat, and oral glucose tolerance test results, which are more informative than BMI, according to Peter Attia. Achieving metabolic health is defined by having five key markers in a 'sweet spot', as stated by Paul Saladino. Improvements in blood glucose and lipid markers can occur quickly with exercise and calorie control, even with 5% weight loss, notes Andrew Huberman. Paul Saladino also suggests that adding carbohydrates to the diet can improve metabolic markers like lowering fasting blood sugar.
Andrew Huberman argues that the idea that 'a calorie is a calorie' is incorrect when mitochondrial function is inhibited. Paul Saladino states that sedentary lifestyles and sleep deprivation negatively affect metabolic health, and that fear of blood sugar spikes and insulin is harmful for humans in the long run. Bryan Johnson claims that ingesting 60g of sugar contributes to the development of metabolic syndrome. Paul Saladino also suggests that excess polyunsaturated fats are a primary driver of metabolic dysfunction, metabolic syndrome, and diabetes. Peter Attia notes that refined starches and sugars negatively affect biology by raising insulin, promoting fat storage, increasing hunger, affecting brain chemistry, locking fat in cells, and slowing metabolism. Paul Saladino claims that consuming sodas with high fructose corn syrup, caramel coloring, and other additives can lead to obesity, diabetes, unhappiness, and irritability. Paul Saladino (2x) states that most individuals do not want to be in a constant state of ketosis, as muscle insulin sensitivity and glucose disposal are desirable for metabolic health. Paul Saladino (2x) also claims that caloric restriction only improves metabolic function in obese humans, and there are no good human trials showing benefits for otherwise healthy individuals. Andrew Huberman notes that trans fats are harmful because the trans double bond cannot be broken down by vertebrate desaturases, leading to accumulation in arteries and the liver and causing chronic metabolic disease and insulin resistance. David Sinclair suggests that SIRT1 plays a minor role in metabolism and is not the key mediator of NAD. Paul Saladino states that stacking multiple drugs like lisinopril and diuretics to manage progressive health issues without addressing underlying causes can lead to poor health outcomes, such as heart attacks, even when taking medications. Paul Saladino also notes that Chris Palmer experienced metabolic problems in his late 20s, including elevated blood pressure, decreased HDL cholesterol, and high triglycerides, which he now attributes to following an ultra low-fat diet.
The verdict could change if there were new findings clarifying the precise reasons why ectopic fat accumulation leads to metabolic dysfunction, or if the differences in metabolic health outcomes between visceral and subcutaneous fat were better understood, as noted by Peter Attia. Further understanding of why some individuals consume high carbohydrates without adverse effects, as mentioned by Paul Saladino, could also alter recommendations. Rhonda Patrick suggests that individuals with good fasting insulin and blood glucose levels may still benefit from a ketogenic diet, indicating an area of uncertainty that could shift the verdict with more definitive evidence.
Mechanistic and trial evidence converge on a real, replicable effect.
Mechanistic and trial evidence converge on a real, replicable effect.
Mechanistic and trial evidence converge on a real, replicable effect.
The intervention improves the primary outcome at standard doses in healthy adults.
Mechanistic and trial evidence converge on a real, replicable effect.
Most of the support comes from short or small studies.
Most of the support comes from short or small studies.
Confounding and publication bias inflate the apparent benefit.
Animal-model results don't translate to the human protocol being recommended.
Most of the support comes from short or small studies.